Neurological disease-focused biotech MapLight Therapeutics progressed plans for a $227 million Nasdaq initial public offering by employing a Securities Act provision allowing registration statements to become effective during reduced SEC operations caused by a federal shutdown. The company is developing a schizophrenia drug targeting muscarinic receptors and is also pursuing Alzheimer’s psychosis. The IPO aims to fuel further development while navigating regulatory challenges posed by government funding gaps.